NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 10/2/2026 10:32 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Vincerx Pharma Stock (NASDAQ:VINC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vincerx Pharma alerts:Sign Up Key Stats Today's Range$0.0150▼$0.015050-Day Range$0.0002▼$0.015052-Week Range$0.00▼$0.07Volume801 shsAverage Volume4,664 shsMarket Capitalization$78.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company’s research has centered on treatments designed to selectively affect cancer cells while limiting exposure to healthy tissue. Vincerx’s pipeline has included enitociclib, formerly known as VIP152, an oral, selective cyclin-dependent kinase 9 (CDK9) inhibitor investigated for hematologic malignancies such as diffuse large B-cell lymphoma and acute myeloid leukemia. The company has also developed small-molecule drug conjugates, including VIP236, as part of its efforts to deliver anticancer agents directly to tumors. Founded in 2019 and headquartered in Palo Alto, California, Vincerx has operated primarily as a U.S.-based drug development company, conducting research and clinical activities through collaborations and clinical studies. Its programs and corporate strategy have evolved as it has advanced and evaluated its oncology pipeline.AI Generated. May Contain Errors. Read More Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VINC Stock News HeadlinesAntibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 DrugsApril 14, 2026 | finance.yahoo.comVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...July 16, 2025 | gurufocus.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution ProposalJuly 16, 2025 | globenewswire.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - MorningstarJuly 9, 2025 | morningstar.comMVincerx Pharma, Inc. Common Stock (VINC) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to StockholdersJuly 7, 2025 | globenewswire.comVincerx Pharma, Inc. (VINC) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comSee More Headlines VINC Stock Analysis - Frequently Asked Questions How have VINC shares performed this year? Vincerx Pharma's stock was trading at $0.0126 on January 1st, 2026. Since then, VINC shares have increased by 19.0% and is now trading at $0.0150. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) released its quarterly earnings data on Thursday, August, 8th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($3.40) by $2.40. When did Vincerx Pharma's stock split? Shares of Vincerx Pharma reverse split on the morning of Tuesday, January 28th 2025.The 1-20 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vincerx Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and Company Calendar Last Earnings8/08/2024Today10/03/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VINC CIK1796129 Webvincerx.com Phone650-800-6676FaxN/AEmployees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)($5.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-248.33% Return on Assets-132.73% Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.50 per share Price / Book0.00Miscellaneous Outstanding Shares5,234,000Free Float1,891,000Market Cap$78.51 thousand OptionableNot Optionable Beta1.46 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:VINC) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersLarry's Three-Step Strategy Revealed at The Dollar Trap SummitLarry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocu...Brownstone Research | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
